Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.

Yoo CB, Chuang JC, Byun HM, Egger G, Yang AS, Dubeau L, Long T, Laird PW, Marquez VE, Jones PA. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila). 2008 Sep; 1(4):233-40.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.